Nexstim Plc announces signing of an Independent Selling Representative Agreement in the U.S. with Surgical Solutions, Inc.

Press release, Helsinki, 8 March 2017 at 3 pm

Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company"), a medical technology company with a pioneering navigated non-invasive brain stimulation system, announces that its wholly owned subsidiary Nexstim Inc. has signed a new Independent Selling Representative Agreement in the U.S. with Surgical Solutions, Inc. to represent the Nexstim Brain Mapping NBS System.  

Surgical Solutions has excellent relationships with neurosurgeon community in Texas based on more than 30 years of experience promoting neurosurgical technologies. It currently represents a number of innovative and valuable products for neurosurgical procedures providing a strong platform to promote the Nexstim Brain Mapping NBS System. 

Commenting on the event, John Liedtky, General Manager U.S. stated: "Our partnership with Surgical Solutions is another key step in the Company's commercial strategy in the US, which is based around signing a number of Independent Selling Representative Agreements.  We look forward to collaborating with the Surgical Solution team as we look to increase awareness and adoption of the Nexstim Brain Mapping NBS System in Texas, a key market in the U.S."

NEXSTIM PLC
Martin Jamieson, Chairman and CEO

Further information is available on the website www.nexstim.com or by telephone:

Nexstim                                                                +447715163942
Martin Jamieson, Chairman and CEO  [email protected]

Citigate Dewe Rogerson                             +44 (0)207 2821066
Katja Stout                                           [email protected]

About Nexstim Plc
Nexstim is a medical technology company which has pioneered its technology in brain diagnostics with the Navigated Brain Stimulation (NBS) system. It is the first and only FDA cleared and CE marked system based on navigated Transcranial Magnetic Stimulation (nTMS) for pre-surgical mapping of the speech and motor cortices of the brain. Based on the same technology platform, the Company has developed a system called Navigated Brain Therapy (NBT®) which is CE marked for the treatment of chronic neuropathic pain, major depression and stroke. Nexstim shares are listed on the Nasdaq First North Finland and Nasdaq First North Sweden. For more information please visit www.nexstim.com

Attachments:

http://www.globenewswire.com/NewsRoom/AttachmentNg/6b673dd7-cc91-4b42-a673-f86098174090